Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer

Current Pharmaceutical Design

Volumn 18, Issue 25, 2012, Pages 3754-3769

  Monk, Bradley J ^a   Dalton, Heather ^a   Benjamin, Ivor ^a   Tanović, Adnan ^b  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PharmaMar   (Spain)

Author keywords

Ovarian cancer; Pegylated liposomal doxorubicin; PLD; Trabectedin; Yondelis

Indexed keywords

ANTHRACYCLINE DERIVATIVE; APREPITANT; BRCA2 PROTEIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; PACLITAXEL; TOPOTECAN; TRABECTEDIN;

AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; DNA DAMAGE; DNA REPAIR; DRUG APPROVAL; DRUG ELIMINATION; DRUG MARKETING; DRUG SYNTHESIS; DRUG TOLERANCE; DRUG TREATMENT FAILURE; EUROPEAN UNION; HUMAN; LICENSING; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; NEUTROPENIA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SIDE EFFECT; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; XERODERMA PIGMENTOSUM;

ANTINEOPLASTIC AGENTS; DIOXOLES; FEMALE; HUMANS; OVARIAN NEOPLASMS; RECURRENCE; TETRAHYDROISOQUINOLINES;

EID: 84867525162     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802002814     Document Type: Article

References (116)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389-93.
3. Armstrong DK, Blessing JA, Look KY, Schilder R, Nunez ER. A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group Study. Invest New Drugs 2003; 21: 373-7.
4. Kaye S. Management of partially platinum-sensitive relapsed ovarian cancer. Eur J Canc Supplements 2008; 6: 16-21.
5. Blackledge G, Lawton F, Redman C, Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 1989; 59: 650-3.
6. Ledermann JA, Raja F. Management strategies for partially platinum-sensitive ovarian cancer. Am J Cancer 2006; 5: 341-54.
7. Pujade-Lauraine E, Vergote I, Pignata S, Kristensen G. Optimizing management of recurrent epithelial ovarian cancer with non-platinum-based chemotherapy. Clinical Ovarian Cancer 2008; 1: 139-40.
8. Bookman MA. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist 1999; 4: 87-94.
9. See HT, Freedman RS, Kudelka AP, et al. Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance. Int J Gynecol Cancer 2005; 15: 209-16.
10. Pignata S, Ferrandina G, Scarfone G, et al. Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study. Oncology 2006; 71: 320-6.
11. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002; 7: 20-8.
12. Gadducci A, Tana R, Teti G, Zanca G, Fanucchi A, Genazzani AR. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Int J Gynecol Cancer 2008; 18: 615-20.
13. Pignata S, De Placido S, Biamonte R, et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer 2006; 6: 5.
14. Mutch DG, Orlando M, Goss T,et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007; 25: 2811-8.
15. Lortholary A, Largillier R, Weber B, et al. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). Ann Oncol 2011; doi:10.1093/annonc/mdr149.
16. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099-106.
17. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006; 24: 4699-707.
18. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15: 2183-93.
19. Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004; 95: 1-8.
20. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312-22.
21. Pujade-Lauraine E, Mahner S, Kaern J, et al. A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG). J Clin Oncol 2009; 27: 2009 ASCO Annual Meeting suppl; abstr LBA5509.
22. Cuevas C, Francesch A. Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem. Nat Prod Rep 2009; 26: 322-37.
23. Carter NJ, Keam SJ. Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 2007; 67: 2257-76.
24. D'Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 2010; 9: 2157-63.
25. Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer. J Clin Oncol 2010; 28: 3107-14.
26. Poveda A, Vergote I, Tjulandin S, et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol 2010; 22: 39-48.
27. Kaye SB, Colombo N, Monk BJ, et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. Ann Oncol 2010; 22: 49-58.
28. Herrero AB, Martin-Castellanos C, Marco E, Gago F, Moreno S. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 2006; 66: 8155-62.
29. Aune GJ, Furuta T, Pommier Y. Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action. Anticancer Drugs 2002; 13: 545-55.
30. Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW. DNA sequence-and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996; 35: 13303-9.
31. Zewail-Foote M, Hurley LH. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 1999; 42: 2493-7.
32. Friedman D, Hu Z, Kolb EA, Gorfajn B, Scotto KW. Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res 2002; 62: 3377-81.
33. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008; 14: 1291-5.
34. Scotto KW. ET-743: more than an innovative mechanism of action. Anticancer Drugs 2002; 13 Suppl 1: S3-6.
35. Schoffski P, Casali PG, Taron M, et al. DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743). J Clin Oncol 2006; 24: 9522.
36. Martinez N, Sanchez-Beato M, Carnero A, et al. Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. Mol Cancer Ther 2005; 4: 814-23.
37. Takebayashi Y, Pourquier P, Zimonjic DB, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcriptioncoupled nucleotide-excision repair. Nat Med 2001; 7: 961-6.
38. Damia G, Silvestri S, Carrassa L, et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 2001; 92: 583-8.
39. Erba E, Bergamaschi D, Bassano L, et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 2001; 37: 97-105.
40. Tavecchio M, Natoli C, Ubezio P, Erba E, D'Incalci M. Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach. Cell Prolif 2007; 40: 885-904.
41. Tavecchio M, Simone M, Erba E, et al. Role of homologous recombination in trabectedin-induced DNA damage. Eur J Cancer 2008; 44: 609-18.
42. Soares DG, Escargueil AE, Poindessous V, et al. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci U S A 2007; 104: 13062-7.
43. Venkitaraman AR. Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu Rev Pathol Mech Dis 2009; 4: 461-87.
44. ®) in advanced pre-treated sarcomas. EJC Supplements 2007; 5: 403-4 (abstract 7505).
45. th ESMO European Society for Medical Oncology, september 20-24, 2009. Berlin): 451-2.
46. Allavena P, Signorelli M, Chieppa M, et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 2005; 65: 2964-71.
47. Germano G, Frapolli R, Simone M, et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res; 70: 2235-44.
48. Bowman A, Twelves C, Koekman K, et al. Phase I clinical and pharmacokinetic (PK) study of Ecteinascidin-743 (ET-743) given as a one hour infusion every 21 days. Ann Oncol 1998; 9: 118, abstract #452.
49. Forouzesh B, Hidalgo M, Denis L, et al. Phase I and pharmacokinetic study of ET-743, a minor groove DNA binder, administrated weekly to patients with advanced cancer. Proc Am Soc Clin Oncol 2001; 20: Abstract 373.
50. Forouzesh B, Hidalgo M, Chu Q, et al. Phase I and pharmacokinetic study of trabectedin as a 1-or 3-hour infusion weekly in patients with advanced solid malignancies. Clin Cancer Res 2009; 15: 3591-9.
51. Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004; 22: 1480-90.
52. Ryan DP, Supko JG, Eder JP, et al. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res 2001; 7: 231-42.
53. Ryan DP, Puchalski T, Supko JG, et al. A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. Oncologist 2002; 7: 531-8.
54. Taamma A, Misset JL, Riofrio M, et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol 2001; 19: 1256-65.
55. Twelves C, Hoekman K, Bowman A, et al. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer 2003; 39: 1842-51.
56. van Kesteren C, Cvitkovic E, Taamma A, et al. Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. Clin Cancer Res 2000; 6: 4725-32.
57. Villalona-Calero MA, Eckhardt SG, Weiss G, et al. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin Cancer Res 2002; 8: 75-85.
58. Puchalski TA, Ryan DP, Garcia-Carbonero R, et al. Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intra-venous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol 2002; 50: 309-19.
59. van Kesteren C, Twelves C, Bowman A, et al. Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1-and 3-h infusion in a phase I study. Anticancer Drugs 2002; 13: 381-93.
60. Delaloge S, Yovine A, Taamma A, et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity. J Clin Oncol 2001; 19: 1248-55.
61. Perez-Ruixo JJ, Zannikos P, Hirankarn S, et al. Population pharmacokinetics of trabectedin (ET-743) in subjects with cancer. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings Part I) 2006; 24: 2030.
62. Perez-Ruixo JJ, Zannikos P, Hirankarn S, et al. Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients. Clin Pharmacokinet 2007; 46: 867-84.
63. Beumer JH, Rademaker-Lakhai JM, Rosing H, et al. Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer. Cancer Chemother Pharmacol 2007; 59: 825-37.
64. Brandon EF, Sparidans RW, Guijt KJ, et al. In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs 2006; 24: 3-14.
65. Beumer JH, Buckle T, Ouwehand M, et al. Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype. Invest New Drugs 2007; 25: 1-7.
66. Beumer JH, Rademaker-Lakhai JM, Rosing H, Lopez-Lazaro L, Beijnen JH, Schellens JH. Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer. Invest New Drugs 2005; 23: 429-36.
67. Donald S, Verschoyle RD, Greaves P, et al. Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat. Cancer Res 2003; 63: 5902-8.
68. Sessa C, De Braud F, Perotti A, et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005; 23: 1867-74.
69. Dileo P, Casali PG, Bacci G, et al. Phase II evaluation of 3-hr infusion ET-743 in patients with recurrent sarcomas. Proc Am Soc Clin Oncol 2002; 21: 408 (abstract 1628).
70. Grosso F, Dileo P, Sanfilippo R, et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer 2006; 42: 1484-90.
71. Beumer JH, Schellens JH, Beijnen JH. Hepatotoxicity and metabolism of trabectedin: a literature review. Pharmacol Res 2005; 51: 391-8.
72. Paz-Ares L, Lopez-Pousa A, Poveda A, et al. Trabectedin in pretreated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Invest New Drugs 2010; 30(2): 729-40.
73. ®; trabectedin. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/hu man/medicines/000773/human_med_001165.jsp&murl=menus/medicines/medicines.jsp&jsenabled=true. Accessed December 2010. 2010.
74. McCrea JB, Majumdar AK, Goldberg MR, et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 2003; 74: 17-24.
75. Meco D, Colombo T, Ubezio P, et al. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother Pharmacol 2003; 52: 131-8.
76. Takahashi N, Li WW, Banerjee D, Scotto KW, Bertino JR. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res 2001; 7: 3251-7.
77. Sessa C, Perotti A, Noberasco C, et al. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur J Cancer 2009; 45: 1153-61.
78. Blay JY, von Mehren M, Samuels BL, et al. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Clin Cancer Res 2008; 14: 6656-62.
79. von Mehren M, Schilder RJ, Cheng JD, et al. A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann Oncol 2008; 19: 1802-9.
80. Vidal L, Magem M, Barlow C, et al. Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors. Invest New Drugs 2010; Epub ahead of print.
81. Messersmith WA, Jimeno A, Ettinger D, et al. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol 2008; 63: 181-8.
82. Papadopoulos KP, Chu Q, Patnaik A, et al. Phase I and pharmacokinetic (PK) study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors. J Clin Oncol 2006; 24: 2029.
83. Sessa C, Cresta S, Noberasco C, et al. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours. Eur J Cancer 2009; 45: 2116-22.
84. Salazar R, Pardo B, Majem M, et al. Phase I clinical and pharmacological trial of trabectedin (T) in 3 hour infusion every 3 weeks (3h/q3w) in patients with advanced cancer and hepatic function disorder. J Clin Oncol 2006; 24: 2080.
85. Lau L, Supko JG, Blaney S, et al. A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study. Clin Cancer Res 2005; 11: 672-7.
86. Manikhas GM, Dirix L, Vermorken JB, et al. A single-blind, placebo controlled, sequential design study evaluating the potential effects of trabectedin on the QT intervals. J Clin Oncol 2010; 28: Abstract: e13096.
87. Krasner CN, McMeekin DS, Chan S, et al. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 2007; 17: 1618-24.
88. 2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol 2009; 20: 1794-802.
89. Del Campo JM, Munoz-Couselo E, Diaz de Corcuera I, Oaknin A. Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer. Expert Rev Anticancer Ther 2010; 10: 795-805.
90. McMeekin S, Del Campo JM, Colombo N, et al. Trabectedin (T) in relapsed ovarian cancer (ROC): a pooled analysis of three phase II studies. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2007, Part I, Vol 25, No.18S (June 20, Supplement) 2007: 5579.
91. ®-Assessment report for Yondelis. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000773/WC500059175.pdf. Accessed May 2011.
92. ®-Assesment report for Yondelis. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000773/WC500059175.pdf. In: editor.^editors. ed. p.
93. Sessa C, Braud F, Cresta S, et al. A phase I combination study of split-dose short infusion trabectedin and doxorubicin administered every 21 days in patients with solid tumors. Eur J Cancer 2005; 3: 430.
94. Chu Q, Mita A, Forouzesh B, et al. Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors. Clin Cancer Res 2010; 16: 2656-65.
95. Von Mehren M, Buck D, Temmer E, Elsayed YA, Cohen RB. Phase I study of trabectedin (T) in combination with docetaxel (D) in patients with advanced malignancies. Journal of Clinical Oncology, 2006 2006; ASCO Annual Meeting Proceedings Part I. Vol 24,No. 18S (June 20 Supplement): 2068.
96. Gore L, Rivera E, Lavallee K, et al. Phase I combination study of trabectedin (T) and capecitabine (C) in patients with advanced malignancies. J Clin Oncol 2006; 24: 2079.
97. O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15: 440-9.
98. Carter NJ, Keam SJ. Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer. Drugs 2010; 70: 355-76.
99. Monk BJ, Sill MW, Hanjani P, et al. Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: A phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2010.
100. Sabbatini P, Sill MW, O'Malley D, Adler L, Secord AA. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study. Gynecol Oncol 2008; 111: 455-60.
101. Greimel E, Bottomley A, Cull A, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer 2003; 39: 1402-8.
102. Krasner CN, Poveda A, Herzog T, et al. Health Related Quality of Life/Patient-reported Outcomes in Relapsed Ovarian Cancer: Results from a Randomized Phase III Study of Trabectedin with Pegylated Liposomal Doxorubicin (PLD) versus PLD Alone. J Clin Oncol 2009; 27: Abstract 5526.
103. Vermorken JB, Kelley J, Provencher D, et al. Patient-reported outcomes in patients with relapsed, platinum-sensitive ovarian cancer (ROC): Results from a large randomized phase III trial. Int J Gynecol Cancer 2010; 20: Abstract No00458.
104. Bast RC, Thigpen JT, Arbuck SG, et al. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop. Gynecol Oncol 2007; 107: 173-6.
105. Mirza MR, Lund B, Lindegaard JC,et al. A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin. Gynecol Oncol 2010; 119: 26-31.
106. Ferrero JM, Weber B, Geay JF, et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 2007; 18: 263-8.
107. Rapoport BL, Vorobiof DA, Slabber C, Alberts AS, Hlophe HS, Mohammed C. Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer. Int J Gynecol Cancer 2009; 19: 1137-41.
108. Power P, Stuart G, Oza A, et al. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study. Gynecol Oncol 2009; 114: 410-4.
109. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010; 28: 3323-9.
110. Vasey P, Largillier R, Gropp M, et al. A GCIG randomized phase III study of carboplatin (C) & pegylated liposomal doxorubicin (PLD) (C-D) vs carboplatin (C) & paclitaxel (P) (C-P): CALYPSO results in partially platinum-sensitive ovarian cancer (OC) patients. Eur J Cancer Supplements 2009; 7: 11.
111. Monk BJ, Coleman RL. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds. Int J Gynecol Cancer 2009; 19 Suppl 2: S63-7.
112. Pfisterer J, Ledermann JA. Management of platinum-sensitive recurrent ovarian cancer. Semin Oncol 2006; 33: S12-6.
113. Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Gynecol Oncol 2004; 94: 67-73.
114. Colombo N, Gore M. Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy. Crit Rev Oncol Hematol 2007; 64: 129-138.
115. Kavanagh J, Tresukosol D, Edwards C, et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 1995; 13: 1584-8.
116. Kaye S. Management of partially platinum-sensitive relapsed ovarian cancer. Eur J Canc Supplements 2008; 6: 16-21.